ClinicalTrials.gg
RecruitingNCT07437079Updated Jul 29, 2026

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

A Phase 1 interventional study of NNC6989-0001 and Placebo (NNC6989-0001) in Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 210 studies in Obesity by Novo Nordisk A/S — 51 open to participants now, 69 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Planned enrollment
87th of 169
132 · median 134
Started
2026
with 49 others
Phase 1
87 of 210
24 open now
Primary completion
2027-01
later than 8 of 68 live
Registered
166th of 210
by date

Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 87th largest by planned enrollment of the 169 interventional ones that give a count, is one of 50 that started in 2026, is one of 87 in phase 1, reaches primary completion later than 8 of the 68 other live ones, and was the 166th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

51 of the 210 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

46 more — sign in →

By country, each count listing its studies:

All 51 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 132 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of non-.
  • Age 18-55 years (both inclusive) at the time of signing the .
  • (BMI) (at screening) ≥ 25.0 and ≤ 34.9 kg/m\^2 for Part A (SAD part) and BMI (at screening) ≥ 25.0 and ≤ 39.9 kg/m\^2 for Part B (MAD part) and Part C (meal timing and potentially meal composition).
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, , and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Any body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening.
  • Treatment with any GLP-1 RA or a medication with GLP-1 activity within 90 days before screening
  • Use of prescription or non-prescription medicinal products within 14 days before screening. This includes over the counter medicines such as laxatives, mineral oil, and fat-blocking supplements. Routine multivitamin/mineral supplements at labelled daily doses are permitted; other non-prescription supplements (e.g., high-dose vitamins, weight-loss supplements) are not permitted. Occasional use of over-the-counter acetaminophen or NSAIDs at their labelled doses for mild pain is permitted.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    NNC6989-0001

    Participants receive the investigational drug NNC6989-0001

    Drug: NNC6989-0001

  • Placebo comparator
    Placebo

    Participants receive placebo matched in appearance to the active drug.

    Drug: Placebo (NNC6989-0001)

Interventions

  • DrugNNC6989-0001

    Participants assigned to the active intervention receive NNC6989-0001

  • DrugPlacebo (NNC6989-0001)

    Participants assigned to the placebo, receive placebo matched in appearance to the active drug.

07

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAE) - Part A

    Measure in number of events.

    Time frame: From time of dosing on Day1 until completion of the end of study visit (Day 7)

  2. Number of treatment emergent adverse events (TEAE) - Part B

    Measured in number of events

    Time frame: From time of dosing on Day 1 until completion of the end of study visit (Day 14)

  3. iAUCTG; The incremental area under the blood triglycerides concentration-time curve following meal test - Part C

    Measured in ratio

    Time frame: Following meal test at Day -1, Day 1, Day 7 and Day 13

Secondary outcomes

  1. AUC; the area under the NNC6989-0001 plasma concentration-time curve - Part A

    Measured in hours times nanograms per millilitre(h\*ng/ml).

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 7)

  2. Cmax; the maximum plasma concentration of NNC6989-0001 - Part A

    Measured in nanograms per millilitre(ng/ml).

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 7)

  3. AUC; the area under the NNC6989-0001 plasma concentration-time curve - Part B

    Measured in h\*ng/ml.

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 14)

  4. Cmax; the maximum plasma concentration of NNC6989-0001 - Part B

    Measured in ng/ml.

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 14)

  5. AUC; the area under the NNC6989-0001 plasma concentration-time curve - Part C

    Measured in h\*ng/ml.

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 20)

  6. Cmax; the maximum plasma concentration of NNC6989-0001 - Part C

    Measured in ng/ml.

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 20)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 10 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 27, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Jan 21, 2027
CompletionEst.
Jan 21, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07437079
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 24, 2026
Primary completion
Jan 21, 2027 (estimated)
Completion
Jan 21, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion